Literature DB >> 24093464

Ciprofloxacin 0.3% + dexamethasone 0.1% for the treatment for otitis media.

Joe Walter Kutz1, Peter S Roland, Kenneth H Lee.   

Abstract

INTRODUCTION: Ciprofloxacin 0.3% with dexamethasone 0.1% (ciprofloxacin/dexamethasone) is an ototopical preparation for acute otitis externa, otorrhea with tympanostomy tubes, and is frequently used to treat chronic suppurative otitis media (CSOM). The advantage of topical therapy is the ability to deliver higher concentration of antibiotics to the treatment site when compared with oral or parenteral antibiotics. The delivery of a high concentration of antibiotics significantly decreases treatment failure and makes the development of resistant organisms unlikely. Previous ototopical preparations contained antibiotics such as aminoglycosides that are known to be ototoxic making treatment of otic infections without an intact tympanic membrane difficulty. AREAS COVERED: A literature search of PubMed was performed as the basis for a literature-based discussion on the clinical efficacy of ciprofloxacin/dexamethasone compared to oral antibiotics and ototopical therapy without a steroid component. The potential ototoxicity of ototopical therapies is discussed, including evidence demonstrating the lack of ototoxicity of fluoroquinolone and dexamethasone containing drops. EXPERT OPINION: Because multiple studies have demonstrated that fluoroquinolones are not ototoxic, fluoroquinolone ototopical drops should be a first-line treatment for otorrhea without an intact membrane. The addition of dexamethasone 0.1% to ciprofloxacin 0.3% has been shown to decrease granulation tissue, improve clinical cure and achieve greater rates of bacterial eradication when compared to ciprofloxacin 0.3% alone.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24093464     DOI: 10.1517/14656566.2013.844789

Source DB:  PubMed          Journal:  Expert Opin Pharmacother        ISSN: 1465-6566            Impact factor:   3.889


  4 in total

1.  Gold nanocluster adjuvant enables the eradication of persister cells by antibiotics and abolishes the emergence of resistance.

Authors:  Zhixin Cao; Xiaohua Chen; Jing Chen; Anping Xia; Brian Bacacao; Jessica Tran; Devesh Sharma; Laurent A Bekale; Peter L Santa Maria
Journal:  Nanoscale       Date:  2022-07-21       Impact factor: 8.307

2.  Dexamethasone modulation of MUC5AC and MUC2 gene expression in a generalized model of middle ear inflammation.

Authors:  Joseph E Kerschner; Pawjai Khampang; Wenzhou Hong
Journal:  Laryngoscope       Date:  2015-11-03       Impact factor: 3.325

3.  Determination of the glycosylation-pattern of the middle ear mucosa in guinea pigs.

Authors:  Elisabeth Engleder; Elisabeth Demmerer; Xueyan Wang; Clemens Honeder; Chengjing Zhu; Christian Studenik; Michael Wirth; Christoph Arnoldner; Franz Gabor
Journal:  Int J Pharm       Date:  2015-02-24       Impact factor: 5.875

4.  An extended release ciprofloxacin/dexamethasone hydrogel for otitis media.

Authors:  Matthew Ku; Shirley Cheung; William Slattery; Erik Pierstorff
Journal:  Int J Pediatr Otorhinolaryngol       Date:  2020-08-18       Impact factor: 1.626

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.